Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) was upgraded by research analysts at Chardan Capital to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.
Several other research analysts have also recently issued reports on the company. Citigroup raised Bradmer Pharmaceuticals to a “hold” rating in a research note on Tuesday, February 24th. ATB Cormark Capital Markets cut Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a research note on Thursday, February 5th. Four research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy”.
Get Our Latest Research Report on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Price Performance
See Also
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
